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Abstract 
Review on TNFRSF9 (CD137), with data on DNA, 
on the protein encoded, and where the gene is 
implicated. 
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CD137 is a member of the tumor necrosis factor 
receptor superfamily 9 (TNFRSF9) first identified 
in mice (Kwon 1989, Kwon 1994) and found to 
map to murine chromosome 4 at the 75.5 cM 
position. Schwarz et al. isolated a 1.4-kb full-length 
cDNA from a library constructed from activated 
human T-cell leukemia virus (HTLV) type 1-
transformed human T-lymphocytes (Schwarz 
1993). Schwarz et al. localized the CD137 gene to  
chromosome 1p36, a region that also harbors genes 
of several other members of this receptor family 
(e.g., TNFRSF1B (TNFR2), TNFRSF8 (CD30), 
TNFRSF4 (OX40) and TNFRSF25 (Apo3)) and is 
associated with deletions and rearrangements in 
several malignancies including neuroblastomas, 
myelodysplastic syndrome, and refractory acute 
non-lymphocytic leukemia (Schwarz 1997).  
Human CD137 gene   
Human CD137 consists of 255 amino acids with 
two potential N-linked glycosylation sites 
(Alderson 1994). Hydrophobicity analysis revealed 
amino acids 1-17 to be a putative signal peptide 
followed by an extracellular domain of 169 amino 
acids and then a transmembrane domain of 27 
amino acids between positions 187-213 and lastly a 
short intracellular domain of 42 amino acids 
(Alderson 1994). The molecular weight of the 
protein was calculated to be 27 kDa (Zhou 1995) 
and was shown to be 60% identical to murine 
CD137 (Alderson 1994). Five regions of amino 
acid sequences were conserved between mice and 
human in the cytoplasmic domain an indication that 
these residues might be important for CD137 
function (Alderson 1994).  Murine and human 
CD137 ligands were identified and cloned by 
Alderson et al.(Alderson 1994). 
Figure 1.  Mapping of CD137 gene on chromosome1p36 (from GeneCards CD137 gene). 
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The human TNFSF9 (CD137L) consisted of 254 
amino acids and its gene maps to chromosome 19 
in the region 19p13.3 (Alderson 1994). The human 
CD137-L shows 36% amino acid identity with its 
murine counterpart (Alderson 1994). High-affinity 
binding of huCD137 Fc to either native or 
recombinant human CD137-L was also 
demonstrated (Alderson 1994). The murine CD137 
ligand consists of 309 amino acid polypeptide and 
its gene maps to murine chromosome 17 (Goodwin 
1993).  
Mouse CD137 gene   
The CD137 gene in mice spans approximately 13kb 
and consists of 10 exons, two of them in the 50 
untranslated regions and eight in the coding region 
(Kwon 1994). Nucleotide sequence analysis of 
CD137 showed a single open reading frame, which 
codes for a polypeptide 256 amino acids in length 
with a calculated molecular mass of 27.5kDa 
(Kwon 1994). The first 23 amino acids were shown 
to be a signal peptide, followed by a cysteine-rich 
region, which comprised of four potential TNFR 
motifs, of which the first was partial and the third 
distinct from those of the TNFR (Kwon 1994). 
Almost 30% of the amino acids residing between 
residues 140-185, a part that follows the ligand 
binding domain, were serine or threonines. These 
provide a potential site for O-linked glycosylation 
while amino acids 186-211 form the hydrophobic 
transmembrane domain which is followed by the 
stop-transfer sequence containing several basic 
residues (Kwon 1994).The carboxyl terminal part 
of the cytoplasmic domain contains two short runs 
of three and four acidic residues, respectively, and a 
sequence of five glycines followed by a tyrosine 
(Kwon 1994). 
Transcription 
CD137 was found to be induced on CD4+ and 
CD8+ T cells in mice and humans (Kwon 1989, 
Schwarz 1995, Vinay 1998, Pollok 1993). In mice, 
the expression takes several hours after stimulation, 
increases slowly, culminates at 60 hours and 
declines again by 110 hours (Goodwin 1993, Vinay 
1998, Pollok1994). In humans, CD137 mRNA was 
detected 1.5 hours after stimulation on T 
lymphocytes, reaching maximal levels at 8 hours, 




CD137 is a 30-kDa glycoprotein and exists as both 
a monomer and a 55-kDa dimer on the T cell 
surface (Kwon 1994).The CD137 gene encodes a 
255-amino acid protein with 3 cysteine-rich motifs 
in the extracellular domain, a transmembrane 
region, and a short N-terminal cytoplasmic portion 
containing potential phosphorylation sites (Schwarz 
1993).  
Structure: Bitra et al.determined the crystal 
structure of mCD137 to 2.2 Å resolution and found 
that similar to other TNFRSFs, mCD137 has four 
cysteine rich domains (CRDs). However, the 
organization of CRD1 and the orientation of CRD3 
and CRD4 with respect to CRD2 in the mCD137 
structure distinctly differed from those of other 
TNFRSFs (Bitra 2017). 
Expression 
In humans, CD137 expression has been reported in 
follicular DCs (Lindstedt 2003), monocytes 
(Kienzle 2000), hepatoma cells (Schwarz 1995) and 
blood vessels from individuals with malignant 
tumors (Broll 2001). Expression of CD137 soluble 
form has been reported in the serum of patients 
with rheumatoid arthritis (Michel 1998). Incresed 
expression of CD137 in human peripheral blood 
mononuclear cells post exposure to mitomycin and 
other DNA damaging agents, such as doxorubicin, 
bleomycin and girradiation (Kim 2002). Expression 
of CD137L was observed following stimulation of 
professional antigen presenting cells (APCs) 
including dendritic cells (DCs) and macrophages as 
well as activated B cells in both human and mice 
(Alderson 1994, Goodwin 1993, Pollok 1994, 
Futagawa 2002, DeBenedette 1997). CD137 is also 
expressed by follicular DC, monocytes, mast cells, 
granulocytes, and endothelial cells (Anderson 
2012). Anderson et al. described CD137 protein 
expression by follicular DC in the germinal center 
and scattered paracortical T cells, but not by normal 
germinal-center B cells, bone marrow progenitor 
cells, or maturing thymocytes. CD137 expression 
was also observed on activated natural killer (NK) 
(Malero 1998), dendritic cells (DC)(Futagawa 
2002) as well as neutrophils (Heinisch 2000 ) in 
mice. 
Localisation 
Using immunohistochemical studies on human 
tissue samples to determine in vivo CD137 
expression in non-immune tissue samples, Broll et 
al. found a strong CD137 expression in blood 
vessel walls, on the endothelial layer, and on the 
vascular smooth muscle cells. 
Function 
The CD137L-CD137 pathway is known to co-
stimulate T cells to carry out effector functions such 
as eradication of established tumors (Melero 1997, 
Ye 2002) as well as the broadening of primary and 
memory CD8+ T cell responses (Halstead 2002, 
Bertram 2002). Signals moderated by CD137 have 
been shown to induce a novel subpopulation of 
CD11c+ CD8+ T cells that have strong anti-cancer 
and anti-autoimmune effects (Vinay 2006). A novel 
carbohydrate-mediated interaction between CD137 
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and LGALS9 (Galectin-9 (Gal-9)) was identified 
and it was demonstrated in several immune 
responses that Gal-9 plays a significant role in 
CD137 signaling activities (Madireddi 2014). Gal-9 
binds to terminal galactose moieties of N-linked 
glycans within the CRD4 region of CD137 and 
there is no competition between this binding with 
the binding of CD137 to its natural ligand CD137L 
or to agonist antibodies against CD137 (Bitra 
2017). Bitra et al. also demonstrated that Gal-9 
facilitates signaling and functional activation of 
CD137 in mouse T cells, DCs and NK cells upon 
binding mouse CD137L or agonist antibodies to 
CD137 (Bitra 2017). Once ligated and crosslinked, 
CD137 interacts with the tumor necrosis factor 
(TNF)-associated factors 1 and 2 ( TRAF1 and 
TRAF2), a process that leads to activation of the 
master immuno-regulatory transcription factor NF-
κB (Chester 2016). In T cells, CD137 signaling 
results into upregulation of the anti-apoptotic B-cell 
lymphoma-extra large ( BCL2L1 (Bcl-xl)), B-cell 
lymphoma 2 ( BCL2) pathways and induces 
proliferation and production of pro-inflammatory 
cytokines interferon gamma ( IFNG (IFN-γ)) and 
IL2 (Lee  2002, Snell 2011). Additionally, CD137 
stimulation causes an increase in signaling through 
the T-cell receptor (TCR) and amplifies the 
cytotoxicity of CD8+ T cells (Shuford  1997). 
Similarly, in NK cells, CD137 stimulation enhances 
proliferation, IFN-γ production, and cytolytic action 
(Melero 1998). In DCs, CD137 ligation speeds up 
maturation through upregulation of B7 co-
stimulatory molecules ( CD80 and CD86) and 
elevates survival and production of IL6 and IL12 
(Kuang 2012). Anti-CD137 immunotherapy has 
recently shown promise as a treatment for solid 
tumors and lymphoid malignancies in preclinical 
models (Anderson 2012). The mode of action 
underlying CD137-mediated tumor regression 
consists of multiple, complimentary antitumor 
immune pathways. Mainly, CD137 agonism 
activates a potent, cytotoxic T-cell population that 
can infiltrate and lyse tumors (Curran 2013). In 
addition to direct tumor lysis, CD137 stimulation 
stimulates secretion of type 1 cytokines, creating an 
inflammatory, immunogenic cytokine milieu within 
the tumor microenvironment (Li 2003). Finally, 
CD137 ligation increases the secretion of perforin ( 
PRF1), granzyme and activation of the Fas ligand ( 
FASLG) effector system by both CD8+ T cells and 
NK cells (Morales-Kastresana 2013). 
Implicated in 
Asthma 
Polte et al. used a murine asthma model to 
demonstrate how a single injection of an anti-
CD137 (CD137) mAb prevents the development of 
airway hyper reactivity, eosinophilic airway 
inflammation, excessive mucus production, and 
elevated IgE during a 7 week observation period. 
They further established that the disease is 
completely reversed by anti-CD137 mAb 
administration (Polte 2006). 
Human atherosclerosis 
CD137 is expressed in human atherosclerosis and 
its activation promotes inflammation and disease 
development in murine atherosclerosis (Söderström 
2014). Söderström et al. showed that the minor T 
allele of rs2453021 is associated with increased 
intima-media thickness in the common carotid 
artery and increased risk of incident non-cardiac 
vascular events, thus providing the first human 
genetic evidence for involvement of CD137 in 
atherosclerosis (Söderström 2014). 
Crystalline silica-induced lung 
inflammation and fibrosis 
Li et al. found that CD137 is induced in response to 
crystalline silica injury in lungs and that it is highly 
expressed during development of experimental 
silicosis. The CD137 pathway signaling was 
discovered to enhance inflammatory response and 
promote pulmonary fibrosis induced by crystalline 
silica (Li 2016). 
Colorectal cancer 
Dimberg et al. investigated whether CD137 and 
CD137L protein levels are altered in colorectal 
tumours compared with paired normal tissues. They 
examined CD137 and CD137L plasma levels from 
patients with colorectal cancer. Collectively, they 
observed a significant lower CD137L level in 
cancerous tissue compared with paired normal 
tissue and the difference in CD137L protein level 
was significantly lower in the colon cancer 
subgroup compared with paired normal colon 
tissue. In addition, an elevated CD137 protein level 
in the rectal cancer subgroup compared with paired 
normal rectal tissue was observed. Higher soluble 
CD137 protein concentration was detected in the 
plasma of patients with a tumour localised in the 
colon compared to those with a tumour localised in 
the rectum. A tendency of higher CD137L protein 
concentration in the plasma from patients with 
colon tumour localization was observed. They also 
observed a strong correlation between plasma 
concentrations of CD137 and CD137L proteins. 
Their work revealed how different expression levels 
of CD137 and CD137L in the colon and rectum 
may indicate that various mechanisms are involved 
in the pathogenesis of colorectal cancer and lead to 
dissimilar protective immunity (Dimberg 2006). 
Crohn's disease 
Maerten et al. investigated whether 
CD137/CD137L interactions might be involved in 
the pathogenesis of Crohn's disease (CD) and found 
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that CD137 expression on lamina propria LP cells 
in inflamed and to a lesser extend in non-inflamed 
gut tissue from CD patients. They also found 
elevated CD137 mRNA levels in intestinal CD 
tissue. Their results suggest that CD137/CD137L 
interactions contribute to the persistence of gut 
inflammation in CD (Maerten 2004). 
Type 1 diabetes 
Forsberg et al. reported suppression of type 1 
diabetes (T1D) progression in NOD mice by 
CD137 deficiency.  From their findings, blockage 
of the CD137-CD137 ligand interaction 
significantly delayed T1D onset in NOD mice and 
absence of CD137 or its interaction with CD137 
ligand led to suppression of T1D progression. They 
also demonstrated that soluble CD137 produced by 
regulatory T cells contributed to their autoimmune-
suppressive function in this model. Their results 
suggest that CD137 can either promote or suppress 
T1D development in NOD mice depending on 
where it is expressed (Forsberg 2017). 
Hodgkin lymphoma 
Anderson et al. showed that CD137 protein is 
expressed by a selected group of hematolymphoid 
tumors, including classical Hodgkin lymphoma, T-
cell and NK/T-cell lymphomas, and follicular 
dendritic cells neoplasms (Anderson 2012). 
Malignant and benign tumors 
In the 32 healthy tissue samples they examined, 
none contained CD137-positive vessels while 
malignant tumors had a significantly enhanced 
frequency of CD137-expressing blood vessels 
(11/34). In benign tumors (2/14) and in 
inflammatory tissues (2/9) only a minority had 
CD137-expressing vessels (Broll 2001). Salih et al. 
described CD137 expression on various human 
carcinoma cell lines, on cells of solid tumors 
derived from these cell lines, and cells obtained 
from human tumors (Salih 2000). 
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